Results 91 to 100 of about 21,936 (207)

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 531-541, August 2026.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source

Factor XI Inhibition for Ischemic Stroke Secondary Prevention: Pharmacology, Clinical Evidence, and Future Directions

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Ischemic stroke remains a leading cause of death and disability worldwide, and bleeding (particularly intracranial hemorrhage) continues to limit conventional antithrombotic therapy in secondary prevention, even with direct oral anticoagulants.
Federica Ferrari, Roberto Federico Villa
wiley   +1 more source

Nucleotide Metabolism in Health and Disease

MedComm, Volume 7, Issue 8, August 2026.
Nucleotide metabolism, including de novo synthesis, salvage pathways, and catabolism, when dysregulated contributes to cancer, immune disorders, metabolic and urological diseases, and radiation injury. Metabolites such as adenosine, cGAMP, NAD, and cAMP and enzymes like RNR are promising therapeutic targets and biomarkers.
Xiaoying Zhao, Yiyu Zeng, Yike Xu, Shu Rao, Mouna Khouchani, Hassna Soummane, Jingyi Li, Rui Liu   +7 more
wiley   +1 more source

Thrombocytosis and the generation of platelet‐derived microparticles in the pathophysiology of sickle cell disease

British Journal of Haematology, Volume 209, Issue 2, Page 420-431, August 2026.
Thrombocytosis is associated with an increased production of platelet‐derived microparticles from activated platelets, which contribute to vaso‐occlusion in sickle cell disease by perpetuating the cycle of inflammation, procoagulant state and endothelial dysfunction.
Giao N. Lê, Anna Dillon, Owen P. Smith, Corrina McMahon   +3 more
wiley   +1 more source

Underdiagnosed and Undertreated: Obesity and Its Cardiometabolic Burden in Swedish Clinical Practice—Insights From the AROS Database

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6787-6800, August 2026.
ABSTRACT Aims To quantify real‐world diagnosis and treatment of obesity in Sweden, describe cardiometabolic comorbidity burden across obesity classes, and compare long‐term cardiovascular outcomes with the general population. Materials and Methods This population‐based cohort study used the AROS (Analysis of Real‐world data of patients with Obesity in ...
Viveca Ritsinger, Magnus Sundbom, Jonatan Dereke, Åsa Ericsson, Thomas Cars, Maria K. Svensson, Anna Norhammar   +6 more
wiley   +1 more source

Investigator‐Led Research to Improve the Diagnostic Assessment of Platelet Function Disorders: Reflections on the Challenges and Rewards

International Journal of Laboratory Hematology, Volume 48, Issue 4, Page 721-731, August 2026.
ABSTRACT Introduction Investigator‐led research and quality improvement initiatives have led to important improvements in the diagnostic assessment of platelet function disorders (PFD). Methods Personal reflections were used to summarize our contributions to knowledge on PFD diagnostic assessment, pathogenesis, and bleeding risks.
Catherine P. M. Hayward
wiley   +1 more source

Early treatment with inhibitors of P2Y12 receptor in patients with ST-segment elevation myocardial infarction — 2023 ESC recommendations and scientific evidence. Is clinical evidence sufficient to suggest a move towards precision medicine? The ELECTRA-SIRIO 2 investigators’ viewpoint

Cardiology Journal
The 2023 ESC guidelines changed previously recommended a strategy of early treatment in patients with STEMI. Pre-treatment with a P2Y12 receptor inhibitor may be considered in patients undergoing a primary PCI strategy (Class IIb, Level of evidence B ...
Jacek Kubica, Piotr Adamski, Jolita Badariene, Marc Bonaca, Piotr Buszman, Rahima Gabulova, Robert Gajda, Tobias Geisler, Robert Gil, Diana A. Gorog, Paul A. Gurbel, Tomasz Hajdukiewicz, Bartosz Hudzik, Stefan James, Young-Hoon Jeong, Adam Kern, Wacław Kochman, Aldona Kubica, Wiktor Kuliczkowski, Przemysław Magielski, Piotr Niezgoda, Małgorzata Ostrowska, Paolo Raggi, Uzeyir Rahimov, Grzegorz Skonieczny, Jolanta M. Siller-Matula, Giuseppe Specchia, Łukasz Szarpak, Paweł Szymański, Udaya Tantry, Julia Umińska, Eliano Pio Navarese   +31 more
doaj   +1 more source

High-mobility group box 1 increases platelet surface P2Y12 and platelet activation in sickle cell disease

JCI Insight
Thrombosis and inflammation are intimately linked and synergistically contribute to the pathogenesis of numerous thromboinflammatory diseases, including sickle cell disease (SCD).
Deirdre Nolfi-Donegan, Gowtham K. Annarapu, Claudette St. Croix, Michael Calderon, Cheryl A. Hillery, Sruti Shiva   +5 more
doaj   +1 more source

Peripheral Sympathetic Sprouting Drives Neuropathic Pain via Spinal Microglial P2Y12 Activation in a Rat Spinal Nerve Ligation Model. [PDF]

J Pain Res
Yu T, Huang H, Li Z, Yan H.
europepmc   +1 more source

Antithrombotic Therapy in Primary and Secondary Prevention of Coronary Artery Disease. [PDF]

J Clin Med
Di Leo G, Spagnolo M, Giacoppo D, Greco A, Capodanno D.   +4 more
europepmc   +1 more source